MX2022003486A - Composiciones terapeuticas de ceramidasa acida y metodos para prepararlas y utilizarlas. - Google Patents

Composiciones terapeuticas de ceramidasa acida y metodos para prepararlas y utilizarlas.

Info

Publication number
MX2022003486A
MX2022003486A MX2022003486A MX2022003486A MX2022003486A MX 2022003486 A MX2022003486 A MX 2022003486A MX 2022003486 A MX2022003486 A MX 2022003486A MX 2022003486 A MX2022003486 A MX 2022003486A MX 2022003486 A MX2022003486 A MX 2022003486A
Authority
MX
Mexico
Prior art keywords
ceramidase
acid ceramidase
acid
precursor
inactive
Prior art date
Application number
MX2022003486A
Other languages
English (en)
Inventor
Edward H Schuchman
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Publication of MX2022003486A publication Critical patent/MX2022003486A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)

Abstract

La presente invención se refiere a una composición terapéutica que incluye una mezcla de ceramidasas y un portador farmacéuticamente aceptable, en donde la mezcla de ceramidasas incluye un precursor ceramidasa ácida inactiva, y una ceramidasa ácida activa. La Invención se refiere también a un método para tratamiento de ceramidasa ácida, que incluye formular la ceramidasa ácida utilizada en el tratamiento como una mezcla de ceramidasas, en donde la mezcla de ceramidasas incluye un precursor ceramidasa ácida inactiva, y una ceramidasa ácida activa. La invención se refiere además a un método para producir una composición terapéutica, que incluye proveer un medio que contiene un precursor ceramidasa ácida inactiva; incubar el medio bajo condiciones que son efectivas para transformar una porción del precursor ceramidasa ácida inactiva en ceramidasa ácida activa; y precursor ceramidasa ácida inactiva para activar la ceramidasa ácida; y recuperar el medio incubado como una mezcla de ceramidasas que comprende el precursor ceramidasa ácida inactiva y una ceramidasa ácida activa. La presente invención se refiere también a la preparación de una composición terapéutica de una ceramidasa que carece de esfingomielinasa ácida.
MX2022003486A 2013-03-14 2015-09-11 Composiciones terapeuticas de ceramidasa acida y metodos para prepararlas y utilizarlas. MX2022003486A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784594P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
MX2022003486A true MX2022003486A (es) 2022-04-25

Family

ID=51625420

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012471A MX2015012471A (es) 2013-03-14 2014-03-13 Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
MX2022003486A MX2022003486A (es) 2013-03-14 2015-09-11 Composiciones terapeuticas de ceramidasa acida y metodos para prepararlas y utilizarlas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012471A MX2015012471A (es) 2013-03-14 2014-03-13 Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.

Country Status (14)

Country Link
US (3) US9937246B2 (es)
EP (2) EP2968479B1 (es)
JP (4) JP6832158B2 (es)
CA (1) CA2905449A1 (es)
DK (1) DK2968479T3 (es)
ES (1) ES2739811T3 (es)
HK (1) HK1220399A1 (es)
HR (1) HRP20191361T1 (es)
HU (1) HUE046113T2 (es)
IL (4) IL241390B (es)
MX (2) MX2015012471A (es)
PL (1) PL2968479T3 (es)
PT (1) PT2968479T (es)
WO (1) WO2014160390A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
WO2013036875A1 (en) 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
ES2739811T3 (es) * 2013-03-14 2020-02-04 Icahn School Med Mount Sinai Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas
WO2018132667A1 (en) 2017-01-13 2018-07-19 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating farber disease
AU2019214519A1 (en) * 2018-02-02 2020-06-18 Aceragen, Inc. Methods for treating Farber disease
SG11202007508TA (en) 2018-03-27 2020-09-29 Enzyvant Therapeutics Gmbh Farber disease markers and uses thereof
US20210244827A1 (en) * 2018-06-29 2021-08-12 Icahn School Of Medicine At Mount Sinai Anc80 encoding sphingolipid-metabolizing proteins
WO2020152532A1 (en) 2019-01-23 2020-07-30 Enzyvant Therapeutics Gmbh Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585793A5 (es) 1974-02-01 1977-03-15 Nestle Sa
JPS5322158B2 (es) 1974-05-02 1978-07-06
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
IT1130242B (it) 1980-02-01 1986-06-11 Anic Spa Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1990011353A1 (en) 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5382524A (en) 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
AU5950694A (en) 1992-12-30 1994-08-15 George Joe Revis Anticaries compositions
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
DE69407292T2 (de) 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
DE69835367T2 (de) 1997-10-29 2007-08-02 Genzyme Corp., Framingham Gentherapie für gaucher-krankheit
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6596509B1 (en) 1998-07-10 2003-07-22 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type III secretion systems
US7018628B1 (en) 1998-07-24 2006-03-28 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
US6258581B1 (en) 1998-08-20 2001-07-10 Takara Shuzo Co., Ltd. Ceramidase gene
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6767741B1 (en) 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
JP2003516122A (ja) 1999-10-13 2003-05-13 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｄａｐキナーゼのショートセグメント
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
US7850984B2 (en) 2000-02-15 2010-12-14 The General Hospital Corporation Protection of the female reproductive system from natural and artificial insults
US20030215435A1 (en) 2000-04-06 2003-11-20 Berent Susan L Expression system for effeiciently producing clinically effective lysosomal enzymes (glucocerebrosidase)
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2002239721C1 (en) 2000-12-22 2008-04-24 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
EP1234816B1 (de) 2001-02-23 2004-06-30 Biofrontera Pharmaceuticals GmbH Scyphostatin-Analoga als SMase-Inhibitoren
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
BRPI0307074A2 (pt) 2002-01-25 2017-06-20 Genzyme Corp meios sem soro para condrócitos e métodos para seu uso
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
DE10239531A1 (de) 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
EP1431399A1 (en) 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
NZ588323A (en) 2003-07-17 2012-04-27 Pacific Edge Biotechnology Ltd Markers for the detection of gastric cancer
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US8017394B2 (en) 2004-10-01 2011-09-13 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US7273756B2 (en) 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
CA2585645C (en) 2004-10-29 2014-10-21 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
JP2008537143A (ja) 2005-04-19 2008-09-11 バーミリオン， インコーポレイテッド アルツハイマー病のためのバイオマーカーであるサポシンｄ及びｆａｍ３ｃ
US20070162992A1 (en) 2006-01-09 2007-07-12 Mcgill University Metabolomic determination in assisted reproductive technology
WO2007089734A2 (en) 2006-01-27 2007-08-09 Eastern Virginia Medical School Proteomic fingerprinting of human ivf-derived embryos: identification of biomarkers of developmental potential
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
AU2007241622A1 (en) 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
WO2007136635A1 (en) 2006-05-16 2007-11-29 Musc Foundation For Research Development Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
CN101490245B (zh) 2006-06-20 2013-01-16 建新公司 无血清培养基及其在软骨细胞扩增中的用途
WO2008086296A2 (en) * 2007-01-05 2008-07-17 Mount Sinai School Of Medicine Acid ceramidase and cell survival
CN101680881B (zh) 2007-04-06 2013-04-24 建新公司 评估细胞和细胞培养物的方法
CA2688240A1 (en) 2007-05-24 2008-12-04 The United States Government As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
NZ601148A (en) 2007-05-31 2012-08-31 Glycan Biosciences Use of pentosan polysulfate for treatment or prophylaxis of allergic rhinitis
FR2924946B1 (fr) 2007-12-18 2010-02-26 Oreal Utilisation cosmetique de proteines de type ceramidase acide
DE102007063535A1 (de) 2007-12-21 2009-06-25 Cycnad Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
BR122019024895B8 (pt) 2008-06-26 2021-07-27 Orphazyme As uso de um agente bioativo capaz de aumentar a concentração intracelular de hsp70
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
JP5721631B2 (ja) 2008-11-06 2015-05-20 ムスク ファウンデーション フォー リサーチ デベロップメント 酸性セラミダーゼのリソソーム親和性阻害剤
WO2010127355A1 (en) 2009-05-01 2010-11-04 Mount Sinai School Of Medicine Method to determine embryo and oocyte quality based on ceramidase
BR112012004377A2 (pt) * 2009-08-28 2017-12-12 Genzyme Corp terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.
PT2490533E (pt) 2009-10-19 2016-01-13 Amicus Therapeutics Inc Novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossómico
HUE029371T2 (en) 2009-11-27 2017-02-28 Genzyme Corp GENZ 112638 For treatment of Gaucher or Fabry disease in combination therapy
WO2012051415A2 (en) 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
WO2013101276A2 (en) 2011-04-01 2013-07-04 Mount Sinai School Of Medicine Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
CN103597356A (zh) * 2011-05-10 2014-02-19 先进流体逻辑公司 酶浓缩与分析
JP6175431B2 (ja) 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
WO2013036875A1 (en) * 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
ES2897825T3 (es) * 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
US9341787B2 (en) 2013-01-02 2016-05-17 Micron Technology, Inc. Apparatus providing simplified alignment of optical fiber in photonic integrated circuits
ES2739811T3 (es) * 2013-03-14 2020-02-04 Icahn School Med Mount Sinai Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas

Also Published As

Publication number Publication date
HRP20191361T1 (hr) 2019-11-01
US10918702B2 (en) 2021-02-16
MX2015012471A (es) 2016-08-03
PL2968479T3 (pl) 2019-10-31
CA2905449A1 (en) 2014-10-02
PT2968479T (pt) 2019-08-07
EP2968479A1 (en) 2016-01-20
EP2968479A4 (en) 2016-07-27
IL304629A (en) 2023-09-01
JP6832386B2 (ja) 2021-02-24
EP3659619A1 (en) 2020-06-03
JP2023015402A (ja) 2023-01-31
JP2019150042A (ja) 2019-09-12
HUE046113T2 (hu) 2020-02-28
WO2014160390A1 (en) 2014-10-02
US9937246B2 (en) 2018-04-10
JP6832158B2 (ja) 2021-02-24
IL272214A (en) 2020-03-31
US20160038574A1 (en) 2016-02-11
US20180193436A1 (en) 2018-07-12
US10238721B2 (en) 2019-03-26
DK2968479T3 (da) 2019-08-12
EP2968479B1 (en) 2019-07-17
IL241390A0 (en) 2015-11-30
IL241390B (en) 2020-03-31
JP2021042227A (ja) 2021-03-18
JP2016520519A (ja) 2016-07-14
BR112015024538A2 (pt) 2018-05-08
IL288427A (en) 2022-01-01
ES2739811T3 (es) 2020-02-04
IL272214B (en) 2022-01-01
HK1220399A1 (zh) 2017-05-05
US20190231857A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
MX2022003486A (es) Composiciones terapeuticas de ceramidasa acida y metodos para prepararlas y utilizarlas.
IN2015KN00262A (es)
MX2015009037A (es) Enjuague nasal con miel.
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
MX2020012596A (es) Procesos e intermedios para preparar un medicamento.
UA110354C2 (uk) Противірусні сполуки
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
IN2015DN01728A (es)
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
TN2012000435A1 (en) Agomelatine hydrochloride hydrate and preparation thereof
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
UA115357C2 (uk) Похідні піридин-4-ілу
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
MX2015009617A (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
PH12014500990A1 (en) Methods for treating gout flares
IN2014MN02269A (es)
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2013011694A (es) Analogos de taxano y abeo-taxanos.
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
MX2015014704A (es) Compuestos, composiciones y métodos para el tratamiento de las enfermedades a través de la inhibición de la actividad del tgf-b.
MX2014010926A (es) Composicion herbaria para el tratamiento de transtornos metabolicos.
IN2013MU03428A (es)
IN2013MU03427A (es)